1515
Annons
INITIATOR PHARMA: INTERIM REPORT JANUARY- SEPTEMBER 2021

Financial Highlights

Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Initiator Pharma A/S was registered on May 2, 2016.

Third Quarter (2021-07-01 – 2021-09-30)
Net revenues were TDKK 0 (0)
EBIT was TDKK -9,056 (-3,068)
Earnings per share was DKK –0.21 (-0.12)
Earnings per share, fully diluted was DKK –0.20 (-0.10)
First Nine Months of the Year (2021-01-01 – 2021-09-30)
Net revenues were TDKK 0 (0)
EBIT was TDKK -15,792 (-8,462)
Earnings per share was DKK –0.64 (-0.33)
Earnings per share, fully diluted was DKK –0.54 (-0.28)
Cash and bank: TDKK 41,394 (8,174)
Solidity: 72% (92%)

Solidity: equity divided by assets.

Business highlights in Q3 2021

  • On July 2nd it was announced that the board had decided to execute on the previously communicated preferential rights issue
  • On July 8th the prospectus for the preferential rights issue was published
  • On July 12th the subscription period of the preferential rights issue began
  • On July 29th it was announced that the rights issue was oversubscribed for a total of 227 percent
  • On August 13th the final day of trading in BTA in connection with the rights issue was announced
  • On September 17th a screening agreement with US National Institute on Drug Abuse to evaluate anti-addictive properties of the company´s preclinical assets was announced
  • On September 24th it was announced that the first patient in the IPED2015 Phase 2b trial was included

Business highlights after this reporting period

  • On October 1st the result of the incentive program in the company was announced
  • On October 8th it was announced that the company had received conditional approval for listing of the companys shares at Nasdaq First North Growth Market in Stockholm
  • On October 18th the Information Memorandum in connection with the change of listing to Nasdaq First North Growth Market was published
  • On October 18th it was announced that the CTA for a Phase 1 proof of principle study in neuropathic pain had been submitted
  • On October 22nd it was announced that the company had been approved for listing at Nasdaq First North Growth Market
  • On October 25th it was announced that the trading of the company’s shares started on October 25th
Source: MFN
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

  • Full tillgång till di.se med nyheter och analyser

  • Tillgång till över 1100 aktiekurser i realtid

  • Dagens industri som e-tidning redan kvällen innan

  • Innehållet i alla Di:s appar, tjänster och nyhetsbrev

3 månader för
197 kr
Spara 1000 kr

Prenumerera

Redan prenumerant?